WonGyun Ahn
Associate Director Qurient
With over nine years of expertise in molecular biology and drug discovery, I currently drive innovative therapeutic strategies in oncology and immunology at Qurient, Inc. I hold a Ph.D. in Pharmacology and previously honed my foundation in research at Samsung Medical Center. My work focuses on steering drug discovery strategies to deliver impactful healthcare advancements.
Seminars
Wednesday 10th June 2026
Pioneering Novel ADC Payloads: Validating Proteasome Inhibitors as a First-in-Class Mechanistic Strategy
11:30 am
- Addressing unmet needs in the current ADC landscape by highlighting the limitations of existing payload classes and the growing necessity for new mechanisms of action
- Introducing the QLi5 proteasome inhibitor platform to demonstrate how non-traditional ADC payloads can be validated and advanced into viable ADC payload strategies
- Discussing how innovative payload mechanisms can broaden the payload landscape for next-generation ADCs
Tuesday 9th June 2026
Beyond Bispecific ADCs & The Next Wave: From Better Delivery to Checkmate Killing
3:15 pm
- Exploring the evolution from traditional to bispecific ADCs
- Discussing the internalization-lethality gap and defining the biological ceiling of efficacy
- Predicting the next wave focused on overcoming resistance
